As a leading service provider in drug discovery and research, BOC Sciences is fully capable and committed to providing one-stop proteolysis targeting molecular drug discovery based on chimeric (PROTAC®). With a comprehensive and advanced platform, we provide target protein services to customers around the world to meet new drug discovery goals.
Introduction
PROTAC is a small molecular complex targeting protein degradation. After the PROTAC molecule enters the cell, the target protein (Protein of interest, POI) ligand in its structure can specifically bind to the corresponding target protein, while the other end can recruit E3 ligase to form a POI-Linker-E3 ligase ternary complex, in which E3 ligase can mediate the ubiquitin binding enzyme E2 to ubiquitin-binding POI. POI labeled by ubiquitin is recognized and degraded by proteasome. In this process, there is no need for the target protein ligand to occupy the binding site for a long time, only the short-term formation of the ternary complex can instantly complete the ubiquitination of the target protein, and PROTAC can be recycled many times in the cell. With the development of the great potential of protein targeted degradation technology, the most exciting thing is that it has the opportunity to use a variety of proteomes that once could not be treated by drugs.
Our Services
- Ligand Design for Target Protein
BOC Sciences is fully competent and dedicated to providing various ligands for target proteins of interest or ligand design service to meet the drug discovery goals of our clients. - Protein Ubiquitination Services
Ubiquitination, also named as ubiquitylation, is a type of protein post-translational modification by adding ubiquitin to protein sequence. We provide a broad range of technologies for ubiquitin research that enable quantification of protein amount and uniquitination modification.
Our Advantages
- Advanced equipment and technique
- Experienced scientific team
- Quantify target protein levels
- Highly reliable and reproducible result
- Data analysis, detailed report with results and discussion
- Quality one-stop service
References:
- Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017). Targeted protein degradation by Protacs. Pharmacology & therapeutics, 174, 138-144.
- Churcher, I. (2018). Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?. Journal of medicinal chemistry, 61(2), 444-452.
- Paiva, S. L., & Crews, C. M. (2019). Targeted protein degradation: elements of Protac design. Current opinion in chemical biology, 50, 111-119.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
